The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD).
Elena Buzzetti, Massimo Pinzani, Emmanuel A Tsochatzis
https://pubmed.ncbi.nlm.nih.gov/26823198/Actively Recruiting
Led by Universitas Diponegoro · Updated on 2024-11-12
50
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are studying the effects of synbiotic supplementation on patients with Metabolic Dysfunction-Associated Fatty Liver Disease MAFLD, a type of fatty liver condition linked to metabolic issues like obesity and diabetes. This research aims to see if synbiotics can change metabolic profiles, insulin levels, inflammatory marker TNF-alpha, and gut microbiota in these patients. The study is designed as a randomized controlled trial to analyze these effects in adults aged 25 to 55 years. Participants are divided into two groups one receives RILLUS, a synbiotic supplement containing specific probiotic bacteria and prebiotic fibers, while the other receives a placebo that looks similar but lacks the live bacteria. Both groups will take two tablets daily for 12 weeks. Hospital visits for control and follow-up occur every 28 days over about four months. Participants will also keep logs to track supplement intake and food consumption. Throughout the study, participants will undergo various assessments including blood tests for hematology, metabolic profiles, insulin, TNF-alpha, and C-reactive protein at three months. Gut microbiota diversity will be evaluated at four months. The researchers will monitor compliance and collect data to understand how synbiotic treatment may influence these health markers. The total study duration for each participant is about four months, including supplementation and follow-up periods.
CONDITIONS
Synbiotics Impact on Insulin and TNF-α in MAFLD: a Gut Microbiota Profile Analysis
H
Hery D Purnomo, Dr
A
Adiyan Pramono, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Universitas Diponegoro
Lead Sponsor
Dr. Kariadi General Hospital Medical Center
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 3 months
Participants take synbiotic or placebo supplements daily to assess effects on insulin, TNF-alpha, and gut microbiota related to MAFLD.
Visits approximately at baseline and monthly during treatment
Duration - 1 month
Participants undergo assessments of gut microbiota diversity and metabolic profiles to monitor longer-term effects after treatment.
1 visit (in-person)
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Elena Buzzetti, Massimo Pinzani, Emmanuel A Tsochatzis
https://pubmed.ncbi.nlm.nih.gov/26823198/Eunju Park, Jin-Ju Jeong, Sung-Min Won...
https://pubmed.ncbi.nlm.nih.gov/34685614/Joo Hyun Oh, Je Hee Lee, Min Seok Cho...
https://pubmed.ncbi.nlm.nih.gov/33801023/Fatemeh Mofidi, Hossein Poustchi, Zahra Yari...
https://pubmed.ncbi.nlm.nih.gov/28345499/Sherin E Mathews, Rekha B Kumar, Alpana P Shukla
https://pubmed.ncbi.nlm.nih.gov/30074500/Marc R Bomhof, Jill A Parnell, Hena R Ramay...
https://pubmed.ncbi.nlm.nih.gov/29779170/Mohammed Eslam, Philip N Newsome, Shiv K Sarin...
https://pubmed.ncbi.nlm.nih.gov/32278004/Vahideh Behrouz, Naheed Aryaeian, Mohammad Javad Zahedi...
https://pubmed.ncbi.nlm.nih.gov/32885440/Herbert Tilg, Timon E Adolph, Alexander R Moschen
https://pubmed.ncbi.nlm.nih.gov/32780879/Jerome Boursier, Anna Mae Diehl
https://pubmed.ncbi.nlm.nih.gov/27063268/Universitas Diponegoro
Lead Sponsor
Dr. Kariadi General Hospital Medical Center
Collaborating Sponsor